DRUG (Bright Minds Biosciences) Tariff Resilience Score: 8/10 (As of Jun. 29, 2026)


DRUG Bright Minds Biosciences Inc DRUG
34 GF Score
Price $65.79
! 2 Warning Signs
View Full Analysis

What is Bright Minds Biosciences Tariff Resilience Score?

Bright Minds Biosciences DRUG +3.35% 34 Tariff Resilience Score is 8 as of Jun. 29, 2026. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,375 Biotechnology companies, Bright Minds Biosciences ranks better than 98.69% on this metric.

Bright Minds Biosciences has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Bright Minds Biosciences has Bright Minds Biosciences Inc has high tariff resilience due to its focus on biotechnology, which often benefits from tariff exemptions. The company's reliance on intellectual property and innovation reduces its exposure to traditional trade tariffs, providing significant protection.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Bright Minds Biosciences might have Highly Resilient.

Bright Minds Biosciences  (NAS:DRUG) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Bright Minds Biosciences Tariff Resilience Score Related Terms

DRUG vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Bright Minds Biosciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Tariff Resilience Score falls into.


DRUG
34GF Score
Bright Minds Biosciences Inc DRUG
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Bright Minds Biosciences (DRUG) has a Tariff Resilience Score of 8 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Bright Minds Biosciences ranks #18 out of 1375 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Bright Minds Biosciences' Tariff Resilience Score too high?
Bright Minds Biosciences' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Bright Minds Biosciences' value of 8 is 100% above this industry median. Based on the distribution chart, Bright Minds Biosciences ranks #18 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bright Minds Biosciences ranks #18 out of 1375 companies for Tariff Resilience Score. This places Bright Minds Biosciences in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Bright Minds Biosciences' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bright Minds Biosciences's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bright Minds Biosciences's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current Tariff Resilience Score is 8 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bright Minds Biosciences Business Description

Other Exchanges DRUG:Canada
Address 19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score

Get the complete analysis for DRUG

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.79
Price